| |
original article |
Date |
Title |
Authors All Authors |
| 1 |
[GO] |
2026―Mar―19 |
Pathological impact of SARS-CoV-2 viroporin on the cardiomyocyte function |
Jin O-Uchi, Bong Sook Jhun |
| 2 |
[GO] |
2025―Dec―20 |
SARS-CoV-2-infected cardiomyocytes exhibit upregulated necroptosis, but no evidence of mitochondrial permeability transition |
C. Gross, S. Chatterjee, B.E. Nilsson-Payant, S.D. Stojanović, H. Kefalakes, C. Bär, et al. (+4) T. Thum, T. Pietschmann, J. Bauersachs, G. Amanakis |
| 3 |
[GO] |
2025―Jun―24 |
Proteomic Insights into Cardiometabolic Remodeling in SARS-CoV-2-Infected Hamsters |
Sogol Sedighi, Ting Liu, Deepthi Ashok, Meghana Prakash, Alexis Tensfeldt, Agnieska Sidor, et al. (+2) D.Brian Foster, Brian O'Rourke |
| 4 |
[GO] |
2025―Jun―24 |
Myocardial Dysfunction in a Syrian Hamster model with COVID-19 |
Cesar Zoni, Namakkal Rajasekaran, Yi Xue, Lillian Zalduando, Chittoor Sai Sudhakar, Colleen Jonsson, Yazhini Ravi |
| 5 |
[GO] |
2024―Dec―22 |
Association of LEF1-AS1 with cardiovascular and neurological complications of COVID-19 |
Mélanie Vausort, Andrew I. Lumley, Hassina Boubakeur, Lu Zhang, Feng Q. Hefeng, Markus Ollert, et al. (+3) Paul Wilmes, Guy Fagherazzi, Yvan Devaux |
| 6 |
[GO] |
2024―Dec―20 |
10043: Prevalence of hypercoagulation in post-acute COVID-19 patients and efficacy of novel anticoagulants as therapeutics in a human ex vivo thrombosis model |
Dan Liao, Aaron Wei Liang Li, Cinthia Wan Ting Phua, Cheryl Xue Pei Chuah, Xiao Xun Yang, Tammy Xin Tian Low, et al. (+5) Matthew Benson, Shoumo Bhattacharya, R. Manjunatha Kini, Mark Yan Yee Chan, Cho Yeow Koh |
| 7 |
[GO] |
2022―Jul―28 |
(Epi)transcriptomics in cardiovascular and neurological complications of COVID-19 |
Amela Jusic, Konstantinos Stellos, Lino Ferreira, Andrew H. Baker, Yvan Devaux |
|
